Table 1.
Summary of included studies.
| Author and year | Country | Study design | Sample size | Age, years, mean (SD) | Body Mass Index, kg/m2, n (%) | Cancer type, n (%) | Cancer stage, n (%) | Cancer treatment, n (%) |
|---|---|---|---|---|---|---|---|---|
| Abbott 2018 | USA | Prospective cohort study | Total n = 601, n = 264 completed follow-up surveys | Group 1 (0 MET-hours/week): 58.9 (10.2) Group 2 (>0–9 MET-hours/week): 57.8 (9.6) Group 3 (>9 MET-hours/week): 57.4 (11.1) |
Overweight/obese Group 1: 79 (87.8) Group 2: 81 (86.2) Group 3: 62 (77.5) |
Ovarian | Stage I–II Group 1: 30 (33.3) Group 2: 32 (34) Group 3: 32 (40) Stage III–IV Group 1: 55 (61.1) Group 2: 58 (61.7) Group 3: 46 (57.5) Unstaged Group 1: 5 (5.6) Group 2: 4 (4.3) Group 3: 2 (2.5) |
S ± adjuvant CT |
| Beesley 2011 | Australia | Prospective cohort study | Total n = 507, n = 266 reported physical activity for all time points | 58 (10) | NR | Ovarian | Stage I–II: 169 (34.2) Stage III–IV: 325 (65.8) |
S ± adjuvant CT |
| Ryan 2012 | Australia | Prospective cohort study | Total n = 40, n = 31 completed second, n = 23 completed third and final assessment | 57 (14.1) | NR | Ovarian 18 (45) Endometrial 11 (28) Cervical 9 (23) Other 2 (5) |
NR | S ± adjuvant CT or CT plus RT as well as S |
| Bifulco 2012 | Italy | Cross sectional study | Total n = 263 Group A (18–45 years) n = 106 Group B (46–65 years) n = 157 |
Group A: 42.8 (2.2) Group B: 55.7 (3.5) |
NR | Uterine 126 (47.9) Ovarian 50 (19) Cervical 40 (15.2) Breast 47 (17.9) |
Group A: Stage I: 92 (86.8); Stage II: 14 (13.2) Group B: Stage I: 122 (77.1); Stage II: 33 (22.3) |
Group A: S 79 (74.5) S + RT 7 (6.6) S + CT 5 (4.7) S + HT 6 (5.6) S + CT + RT 5 (4.7) S + CT + HT 4 (3.8) Group B: S 108 (68.8) S + RT 19 (12.1) S + CT 10 (6.4) S + HT 4 (2.5) S + CT + RT 15 (9.5) S + CT + HT 1 (0.6) |
| Mizrahi 2015 | Australia | Cross sectional study | Total n = 95 | n (%): 40–54: 28 (30); 55–69: 47 (49); ≥70: 20 (21) | 26.5 (6.8) Underweight/healthy: 43 (46); Overweight/obese: 47 (54) |
Ovarian | Stage I: 11 (12) Stage II: 9 (9) Stage III: 31 (33) Stage IV: 31 (33) Unknown 12 (13) |
CT (93%) S (97%) RT (14%) HT (10%) |
| Farrokhzadi 2016 | Australia | Cross sectional study | Total n = 101 | 57.5 (range 19–87) | Mean 27.1 (range 18.7–54.9) | Endometrial 23 Ovarian 59 Cervical 5 Other 13 |
NR | S, CT, RT, targeted therapy 95 |
Abbreviations: SD, standard deviation; n, number; %, percentage; USA, The United States of America; MET, metabolic equivalent; NR, not reported; S, surgery; RT, radiotherapy; CT, chemotherapy; HT, hormonal therapy; CRT, chemoradiotherapy.